Genetic variants in <i>RTEL1</i> influencing telomere length are associated with prostate cancer risk

Gu, Cheng-Yuan; Jin, Sheng-Ming; Qin, Xiao-Jian; Zhu, Yao; Bo, Dai; Lin, Guo-Wen; Shi, Guo-Hai; Ye, Ding-Wei

doi:10.7150/jca.35917

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(24):6170-6174. doi:10.7150/jca.35917 This issue Cite

Research Paper

Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk

Cheng-Yuan Gu^1,2*, Sheng-Ming Jin^1,2*, Xiao-Jian Qin^1,2, Yao Zhu^1,2, Dai Bo^1,2, Guo-Wen Lin^1,2, Guo-Hai Shi^1,2✉, Ding-Wei Ye^1,2✉

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
*These authors contributed equally to this work.

Citation:

Gu CY, Jin SM, Qin XJ, Zhu Y, Bo D, Lin GW, Shi GH, Ye DW. Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. J Cancer 2019; 10(24):6170-6174. doi:10.7150/jca.35917. https://www.jcancer.org/v10p6170.htm

Other styles

Abstract

Telomere length measured in lymphocytes has been evaluated as a potential biomarker for prostate cancer (PCa) risk. Identifying genetic variants that affect telomere length and testing their association with disease could clarify any causal role. We therefore investigated associations between genetic variants in three telomere length-related genes and PCa risk in a case-control study. The influence of these variants on the leukocyte telomere lengths was then appraised by real-time PCR. RTEL1 rs2297441 [odds ratio (OR): 1.23; 95% confidence interval (CI): 1.03-1.46, P = 0.021] and rs3208008 (OR: 1.23; 95% CI: 1.03-1.46) were associated with PCa risk. These two risk single nucleotide polymorphisms (SNPs) (OR: 0.59; 95% CI: 0.39-0.89, P = 0.012 and OR: 0.58; 95% CI: 0.38-0.87, P = 0.009, respectively) and another SNP PARP1 rs1136410 (OR: 1.53; 95% CI: 1.01-2.31, P = 0.043) were also associated with leukocyte telomere length. These findings support that genetic determinants of telomere length may influence PCa risk.

Keywords: prostate cancer, polymorphisms, telomere, susceptibility

Citation styles

APA

Gu, C.Y., Jin, S.M., Qin, X.J., Zhu, Y., Bo, D., Lin, G.W., Shi, G.H., Ye, D.W. (2019). Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. Journal of Cancer, 10(24), 6170-6174. https://doi.org/10.7150/jca.35917.

ACS

Gu, C.Y.; Jin, S.M.; Qin, X.J.; Zhu, Y.; Bo, D.; Lin, G.W.; Shi, G.H.; Ye, D.W. Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. J. Cancer 2019, 10 (24), 6170-6174. DOI: 10.7150/jca.35917.

NLM

CSE

Gu CY, Jin SM, Qin XJ, Zhu Y, Bo D, Lin GW, Shi GH, Ye DW. 2019. Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. J Cancer. 10(24):6170-6174.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.